Translating Hyperpolarized 13C MRI as a Novel Tool to Predict Treatment Response in Pancreatic Cancer

What this Trial Is About

Researchers are evaluating an experimental scan called hyperpolarized carbon-13 pyruvate magnetic resonance imaging (MRI) to assess treatment response in patients with pancreatic ductal adenocarcinoma (PDA) that has spread locally or to other parts of the body. This investigational MRI uses a special contrast agent that shows how tumors process nutrients, potentially providing better information than standard MRI scans with usual contrast agents. The study aims to see if this scan can predict how PDA tumors respond to treatment and relate these changes to tumor size and patient outcomes. Participants are assigned to one of two groups based on their disease status. Those with advanced or non-resectable PDA receive the investigational agent intravenously and undergo MRI scans before starting standard treatment, then again 4 weeks after treatment begins, with an optional scan at 8 weeks. Patients with localized PDA who are candidates for neoadjuvant therapy undergo similar MRI scans before and after starting therapy, with the same optional 8-week scan. Throughout the study, participants also have CT and additional MRI scans, and may move between groups depending on their response and surgical eligibility. During the study, participants undergo imaging assessments including the investigational MRI and CT scans to measure tumor metabolism and size. Researchers track changes in tumor metabolism measures at multiple timepoints and relate these to treatment response using established criteria and survival outcomes. The study also evaluates the repeatability of the investigational scan and compares it with other MRI measures. Participants' health and ability to undergo scans are monitored, and the study may last up to 24 months to assess long-term outcomes.

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer